CagriSema: The Semaglutide + Cagrilintide Combo Targeting 25% Weight Loss

CagriSema represents Novo Nordisk's most advanced attempt to push obesity treatment beyond what semaglutide alone can achieve. By combining the GLP-1 agonist semaglutide with cagrilintide — a long-acting analog of the satiety hormone amylin — in a single weekly injection, the idea is to attack obesity through two complementary biological pathways.

The results so far are impressive. But there's a more nuanced story here than the headline numbers suggest.

How CagriSema Works

Semaglutide (the GLP-1 component) suppresses appetite through hypothalamic signaling, slows gastric emptying, and improves insulin secretion. You know this drug — it's the active ingredient in Wegovy and Ozempic.

Cagrilintide is a long-acting amylin receptor agonist. Amylin is a hormone naturally co-secreted with insulin that signals satiety to the brain through a different pathway than GLP-1. It also slows nutrient absorption and suppresses glucagon release. Pramlintide (Symlin), an older amylin analog, has been used in diabetes for years, but cagrilintide is a newer, more potent, once-weekly version.

The combination targets appetite from two angles: GLP-1 works primarily through the hypothalamus, while amylin works through the area postrema and other brainstem regions. Different brain circuits, same goal — reduced hunger and faster fullness.

Phase 3 Results: The REDEFINE Program

REDEFINE 2 (Obesity Without Diabetes)

The headline trial, REDEFINE 2, enrolled patients with obesity and reported 22.7% mean weight loss at 68 weeks. This exceeded the performance of each component alone and was statistically superior to placebo.

However, it fell short of the ~25% target that Novo Nordisk had projected and analysts had priced in. When REDEFINE 2 results were announced in December 2024, Novo Nordisk's stock dropped significantly — not because 22.7% is bad (it's excellent), but because expectations had been set higher.

REDEFINE 1 (Type 2 Diabetes)

In the diabetes population, CagriSema showed a 2.2% mean HbA1c reduction and 15.6% body weight reduction at 32 weeks in Phase 2. The Phase 3 program in T2DM is ongoing, with results expected in 2026-2027.

CagriSema vs. the Competition

CagriSema sits in the middle of the pack among next-gen drugs. It's better than current approved options, but Eli Lilly's retatrutide (28.7% in TRIUMPH-4) and even Novo's own zenagamtide (22% at just 36 weeks, no plateau) may eventually surpass it.

CagriSema vs. Zenagamtide: Novo's Internal Competition

This is the fascinating subplot. Novo Nordisk has two drugs targeting the same GLP-1 + amylin pathways, and they're effectively racing against each other:

CagriSema is further along in development (Phase 3 complete) but combines two separate molecules — which means more complex manufacturing and a two-chamber delivery device. Zenagamtide is a single molecule that hits both targets, making it simpler to manufacture and potentially easier to formulate as an oral pill.

Novo's CSO Martin Holst Lange has said that if zenagamtide matches CagriSema's performance, it would be the preferred commercial product due to manufacturing advantages. CagriSema may serve as the near-term option (approval 2027-2028) while zenagamtide represents the longer-term platform (approval ~2030).

Timeline and Availability

Novo Nordisk is expected to submit CagriSema for FDA approval based on the REDEFINE program data, with a potential approval in the 2027-2028 timeframe. Pricing has not been announced, but given the dual-drug formulation, it will likely be priced at a premium to existing GLP-1 monotherapies.

What This Means for You

CagriSema won't be available for at least a year. But its development — alongside Wegovy HD, zenagamtide, retatrutide, and orforglipron — signals that the GLP-1 landscape is getting dramatically more competitive. More drugs, more options, and increasing pressure on pricing all benefit patients.

If you're already on a GLP-1 and getting good results, there's no reason to wait for CagriSema. If you've plateaued, the newly approved Wegovy HD 7.2mg (20.7% weight loss) is available now — and future options like CagriSema may provide even more powerful alternatives down the road.